NEW YORK--(BUSINESS WIRE)--Enzo Biochem, Inc. (NYSE:ENZ) today released a new investor presentation that, in light of recently announced approval for the Company’s HCV viral load testing by the New York State Department of Health, centers on an update of Enzo’s strategy providing low cost solutions for meeting reimbursement and cost challenges in the molecular diagnostic market.
